KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Ionis Pharmaceuticals (IONS) over the last 13 years, with Q3 2025 value amounting to $2.3 million.

  • Ionis Pharmaceuticals' Depreciation & Amortization (CF) fell 448.96% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 936.68%. This contributed to the annual value of $9.6 million for FY2024, which is 658.76% down from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $2.3 million for Q3 2025, which was down 448.96% from $2.3 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Depreciation & Amortization (CF) peaked at $4.0 million during Q2 2021, and registered a low of $2.2 million during Q1 2025.
  • Its 5-year average for Depreciation & Amortization (CF) is $3.0 million, with a median of $2.6 million in 2023.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Depreciation & Amortization (CF) surged by 2900.54% in 2021, and later tumbled by 3390.1% in 2023.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Depreciation & Amortization (CF) stood at $3.8 million in 2021, then dropped by 20.8% to $3.0 million in 2022, then dropped by 15.96% to $2.5 million in 2023, then decreased by 11.95% to $2.2 million in 2024, then increased by 0.67% to $2.3 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $2.3 million for Q3 2025, versus $2.3 million for Q2 2025 and $2.2 million for Q1 2025.